Krazati (adagrasib) — Medica
Colon cancer
Initial criteria
- age ≥ 18 years
- unresectable, advanced, or metastatic disease
- KRAS G12C mutation-positive disease
- ONE of the following: (i) prescribed as part of a combination regimen for colon or rectal cancer OR (ii) unable to tolerate combination therapy per prescriber
- previously received a chemotherapy regimen for colon or rectal cancer
Approval duration
1 year